Clinical trials do not need to happen in a clinic. For most nutrition and supplement studies, asking participants to travel to a research site on multiple occasions adds cost, creates scheduling complexity, and excludes anyone who cannot easily get there. None of these constraints serve the quality of the research.
Decentralised clinical trials run the same study design, with the same randomisation and blinding, but collect data remotely. For the outcome types used in most supplement studies, this produces equivalent results at meaningfully lower cost and in less time.
What makes a trial "decentralised"
A decentralised clinical trial (DCT) removes the requirement for participants to attend a physical research site for data collection. Instead:
- Products are shipped directly to participants at home
- Blood and biological samples are collected via validated at-home kits and returned by post
- Questionnaire assessments are completed digitally at the scheduled time points
- Wearable devices collect physiological data continuously throughout the intervention
- Participant check-ins and queries are handled by the trial management team remotely
Participants can join a decentralised trial from anywhere in the UK, provided they meet the study criteria. This replaces the single-site geographic constraint of a traditional trial with a UK-wide participant pool.
Why decentralised design matters for timeline
The single largest cause of trial delays is participant recruitment shortfall. Traditional clinic-based trials recruit from a limited geographic area: people who can realistically travel to the site on the required schedule. This restricts the available pool, slows recruitment, and extends timelines when initial enrolment targets are not met.
Decentralised trials recruit from the entire country. For a study requiring 60 participants meeting specific criteria, the difference between drawing from a 10-mile radius and drawing from the full UK population is the difference between a 4-week recruitment window and a 12-week one. This is one of the main reasons StudySetGo can deliver studies in 6 to 9 months when traditional clinic-based trials take longer.
Why decentralised design matters for dropout rates
Participant dropout is the other major timeline risk in clinical trials. When a participant drops out, you lose their data and may need to extend recruitment to compensate, which adds time and cost.
Remote-first trials generally show lower dropout rates than clinic-based trials. The reason is participant burden: attending a research clinic multiple times over 8 to 12 weeks requires time off work, travel, and schedule planning. Most people find this progressively harder to maintain as the trial progresses. Completing a questionnaire on a phone and returning a blood collection kit by post creates far less friction.
The outcome measures that work best remotely
Decentralised collection is well-suited to the outcomes most commonly measured in nutrition and supplement studies:
- Blood biomarkers. Validated at-home finger-prick collection kits cover a wide range of markers including lipids, glucose, inflammatory markers (CRP, IL-6), vitamins and minerals, hormones, and liver function. Samples are returned by post and processed at an accredited laboratory.
- Cognitive function. Validated digital cognitive test batteries (attention, working memory, processing speed, executive function) are completed on a standard device at home. Many tools used in academic nutrition research have validated remote administration protocols.
- Mood, energy, and wellbeing. Validated patient-reported outcome measures (PROMs) and quality of life questionnaires are specifically designed for remote administration.
- Sleep and activity. Validated wearables collect continuous data on sleep architecture, heart rate variability, step count, and activity intensity throughout the intervention without any participant action required.
- Blood pressure and body weight. Validated home monitoring devices allow participants to collect these measurements at scheduled time points.
Outcomes that still require a clinic visit include DEXA body composition scans, venepuncture for large-volume blood draws, complex imaging, and any procedure requiring a trained clinician. If your study requires these, a hybrid design is possible: remote for routine measurements, in-person for specific assessments.
The outcomes that matter most for supplement brands, blood biomarkers, cognitive function, mood, and sleep, all translate to remote collection with validated methods. We built our trial infrastructure around that reality.
Nathan Phillips, CEO, StudySetGoIs decentralised evidence accepted by regulators and journals?
Yes. Regulators assess methodology, not whether data was collected at a clinic or at home. The requirement is that the collection method is validated and that data integrity is maintained. Both the MHRA and peer-reviewed journals routinely accept DCT evidence for nutrition studies.
From a publications standpoint, decentralised nutrition trials appear regularly in high-quality journals. The study design is described in the methods section; the journal's concern is whether the methods are rigorous, not whether they were clinic-based.
For ASA purposes, what matters is that the study produced credible, published evidence for the specific claim being made. Whether collection happened in a clinic or at home is not the determining factor.
How decentralised design reduces cost
Traditional clinic-based trial costs include: site rental fees, nursing or phlebotomy staff time, participant travel reimbursement, clinical scheduling overhead, and equipment maintenance. These costs apply per visit, so a 3-visit protocol with 60 participants generates 180 clinic appointments.
Decentralised trials replace these with: home collection kit unit costs (lower per sample than a clinic appointment), digital questionnaire platforms (no marginal cost per completion), and postal logistics. For most nutrition study designs, this reduces the direct data collection cost significantly.
The indirect savings are also material. Faster recruitment and lower dropout mean fewer timeline extensions, less contingency budget consumed, and a shorter project management timeline overall.
Frequently asked questions
A decentralised clinical trial runs the study without participants attending a physical site. Data is collected remotely via at-home blood collection kits, validated digital questionnaires, and wearable devices. Participants can join from anywhere in the UK, which expands the recruitment pool and reduces participant burden.
Yes, when validated tools are used. Regulators and journals require validated methodology, not clinic-based collection. At-home collection kits, validated wearables, and digital questionnaire tools all have published validation data. The data produced is equivalent in quality to clinic data for the outcome types used in nutrition studies.
Validated at-home finger-prick collection kits cover lipids (total cholesterol, HDL, LDL, triglycerides), blood glucose and HbA1c, inflammatory markers (CRP, IL-6), vitamins and minerals (D3, B12, iron, omega-3 index), hormones, and liver function markers. Samples are returned by post and processed at an accredited laboratory. Some large-volume analyses still require venepuncture at a clinic.
Remote-first trials generally show lower dropout rates than clinic-based trials. The reduction in participant burden (no travel, no clinic appointments) makes it easier for people to complete the full intervention. Lower dropout means fewer participants need to be recruited to reach your target sample size, which reduces both cost and timeline.